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Abstract
Background: Despite recent discoveries of new molecular targets and pathways, the search for an effective therapy for
Glioblastoma Multiforme (GBM) continues. A newly emerged field, radiogenomics, links gene expression profiles with MRI
phenotypes. MRI-FLAIR is a noninvasive diagnostic modality and was previously found to correlate with cellular invasion in
GBM. Thus, our radiogenomic screen has the potential to reveal novel molecular determinants of invasion. Here, we present
the first comprehensive radiogenomic analysis using quantitative MRI volumetrics and large-scale gene- and microRNA
expression profiling in GBM.
Methods: Based on The Cancer Genome Atlas (TCGA), discovery and validation sets with gene, microRNA, and quantitative
MR-imaging data were created. Top concordant genes and microRNAs correlated with high FLAIR volumes from both sets
were further characterized by Kaplan Meier survival statistics, microRNA-gene correlation analyses, and GBM molecular
subtype-specific distribution.
Results: The top upregulated gene in both the discovery (4 fold) and validation (11 fold) sets was PERIOSTIN (POSTN). The
top downregulated microRNA in both sets was miR-219, which is predicted to bind to POSTN. Kaplan Meier analysis
demonstrated that above median expression of POSTN resulted in significantly decreased survival and shorter time to
disease progression (P,0.001). High POSTN and low miR-219 expression were significantly associated with the
mesenchymal GBM subtype (P,0.0001).
Conclusion: Here, we propose a novel diagnostic method to screen for molecular cancer subtypes and genomic correlates
of cellular invasion. Our findings also have potential therapeutic significance since successful molecular inhibition of
invasion will improve therapy and patient survival in GBM.
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Introduction
Microarray technology is a novel method that allows for the
simultaneous analysis of whole genome gene- and microRNA
expression events [1,2]. This latest breakthrough technology
heralds an age of large-scale discovery of new and effective
therapeutic strategies for Glioblastoma Multiforme (GBM).
However, despite the discovery of many new molecular targets
and pathways [3,4], the search for an effective therapy continues.
Besides the multi-resistant character of GBM [5,6], therapy
failure is thought to occur due to the cancer’s invasive nature and
high migratory potential preventing complete surgical resection
and evading current therapeutic strategies [7,8,9]. Furthermore,
therapy is complicated by intra- and intertumoral molecular and
cellular heterogeneity that is now known to cause some tumors to
respond to a specific drug while another demonstrating resistance
[4,10]. Based on this recent awareness, focus is shifting toward a
more personalized treatment approach. In this regard, in
particular, microRNAs are being increasingly studied. Micro-
RNAs are non-protein coding small RNAs that serve as negative
gene regulators by binding to a specific sequence in the 39UTR of
a target gene, thus regulating gene expression. A single microRNA
potentially targets hundreds of genes; thus, microRNAs were
found to have important roles as tumor suppressors and oncogenes
[11], as well as regulators of various cancer-specific cellular
features, such as proliferation, invasion, and metastasis [12,13,14].
Although certain genetic analyses, such as O6-methylguanine-
DNA-methyltransferase (MGMT) promoter methylation and
isocitrate dehydrogenase 1 (IDH1) status [4,15,16,17], are
frequently used in clinical practice, large scale gene- and
microRNA based cancer characterization is commonly not
performed due to high cost, time and manpower required for
data analysis and interpretation [18]. In order for personalized
medicine to transpire, a cost-effective biomarker that accurately
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needed. Imaging, specifically MRI, is a promising biomarker that
can reflect underlying tumor pathology and biological function. It
can evaluate the entire tumor, including its peritumoral regions
which harbor microscopic invasion of cancer cells [19] and which
typically cannot be surgically removed and thus are rarely
analyzed in the laboratory. It follows that if imaging phenotypes
of GBM obtained from routine clinical MRI studies can be
associated with specific gene and microRNA expression signatures,
imaging phenotypes will serve as non-invasive surrogates for
cancer genomic events and provide important information as to
the diagnosis, prognosis, and optimal treatment. Furthermore, it
will allow for bi-directional imaging phenotype-genotype correla-
tions and discoveries. Thus, a new field termed radiogenomics has
emerged and links specific MRI radiophenotypes with gene
expression profiles [20].
In the past, several studies compared gene expression and MRI
findings [21,22,23,24,25]. However, we present the first compre-
hensive radiogenomic analysis using quantitative MRI volumetrics
and large-scale gene- and microRNA expression profiling in GBM.
In this study, we specifically seek to identify and corroborate
relevant genomic correlates of an edema/cellular invasion GBM
radiophenotype. This is of clinical significance, since cellular
invasion currently is one of the major reasons for therapy failure of
modern multimodal GBM treatment [9]. The discovery of
targetable genes responsible for cell spread and invasion can be
expected to impact modern therapy and patient survival.
Materials and Methods
The collection of the original material and data provided by
The Cancer Genome Atlas (TCGA) project was conducted in
compliance with all applicable laws, regulations and policies for
the protection of human subjects, and any necessary approvals,
authorizations, human subject assurances, informed consent
documents, and IRB approvals were obtained [26].
Patient population
We identified 78 treatment-naı ¨ve GBM patients from TCGA
whom had both gene- and microRNA expression profiles and
pretreatment MR-neuroimaging. The TCGA is a publicly
available resource which has produced a multi-dimensional
genomic and clinical data set in GBM and other cancers [26].
Recently, MR imaging was added to this genomic repository.
Discovery and Validation sets
To increase the robustness and validity of the analysis, the 78
patients were randomly separated into a discovery and validation
Table 1. Discovery (N=26) and validation (N=26) sets.
Discovery set Validation set
Patient FLAIR signal FLAIR Age Gender Patient FLAIR signal FLAIR Age Gender
D1 1 high 54 MALE V1 1 high 17 FEMALE
D2 0.921410705 high 58 MALE V2 0.808427556 high 73 FEMALE
D3 0.903551776 high 65 MALE V3 0.793857093 high 79 MALE
D4 0.792396198 high 64 MALE V4 0.754575125 high 48 MALE
D5 0.684642321 high 63 FEMALE V5 0.740529199 high 14 MALE
D6 0.671335668 high 76 MALE V6 0.732311458 high 55 FEMALE
D7 0.619409705 high 62 MALE V7 0.702995687 high 69 MALE
D8 0.600450225 high 38 MALE V8 0.633232311 high 61 MALE
D9 0.586793397 high 51 MALE V9 0.559511598 high 57 FEMALE
D10 0.489169585 high 43 MALE V10 0.554481874 high 30 FEMALE
D11 0.447893947 high 72 FEMALE V11 0.544737149 high 60 MALE
D12 0.436823412 high 47 FEMALE V12 0.473621634 high 70 MALE
D13 0.431815908 high 55 MALE V13 0.468842522 high 69 MALE
D14 0.272961481 low 69 MALE V14 0.190709873 low 66 MALE
D15 0.244997499 low 54 MALE V15 0.162839492 low 64 MALE
D16 0.228409205 low 63 FEMALE V16 0.15912111 low 71 MALE
D17 0.20064032 low 53 FEMALE V17 0.155373587 low 71 MALE
D18 0.197133567 low 63 FEMALE V18 0.130528034 low 63 MALE
D19 0.184682341 low 40 MALE V19 0.128989393 low 75 FEMALE
D20 0.181475738 low 71 MALE V20 0.123831449 low 50 MALE
D21 0.179684842 low 69 MALE V21 0.121465206 low 17 MALE
D22 0.175007504 low 73 MALE V22 0.117280569 low 52 FEMALE
D23 0.097268634 low 55 FEMALE V23 0.107413451 low 60 MALE
D24 0.088534267 low 64 MALE V24 0.075171931 low 59 FEMALE
D25 0.085067534 low 64 MALE V25 0.059406691 low 66 FEMALE
D26 0.027853927 low 59 FEMALE V26 0.036647045 low 76 MALE
doi:10.1371/journal.pone.0025451.t001
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PLoS ONE | www.plosone.org 2 October 2011 | Volume 6 | Issue 10 | e25451Figure 1. Volumetric brain tumor mapping of FLAIR, Necrosis, and Contrast Enhancement. A 55 year old male patient with a right
temporal GBM. (a) Axial FLAIR image demonstrates segmentation (in blue) of the region of FLAIR hyperintensity corresponding to the area of edema/
tumor infiltration. Notice the segmented enhancement (yellow) and necrosis (orange) that has been segmented on the T1WI post- contrast. (b) The
segmented edema/tumor infiltration (blue), enhancement (yellow) and necrosis (orange) are seen overlaid on a base post- contrast T1WI. (c) Axial
post-contrast enhanced T1WI demonstrates the segmentation of the enhancement (yellow) and necrosis (orange).
doi:10.1371/journal.pone.0025451.g001
Figure 2. Low FLAIR patient. A 67 year old male patient with a right temporo-parieto-occipital GBM. The segmented edema/tumor infiltration
(blue), enhancement (yellow) and necrosis (orange) are seen overlaid on a base post- contrast T1WI. These images demonstrate a patient with a GBM
and a large amount of peritumoral FLAIR hyperintensity reflecting edema and tumor infiltration.
doi:10.1371/journal.pone.0025451.g002
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volume as criteria for further subgrouping the patients, each set
was sub-stratified into high, medium, and low FLAIR volumes
(each consisting of 13 patients) corresponding to volumes of high,
medium, and low peritumoral edema/invasion, respectively. High
and low groups were selected for analysis and compared for
differential genomic expression profiles; this resulted in a total of
52 patients (discovery set N=26, validation set N=26; Table 1).
Image Acquisition and Analysis
All images were downloaded from the National Cancer
Institute’s ‘‘The Cancer Imaging Archive (TCIA)’’ (http://
cancerimagingarchive.net/).
Volume Selection. We used two sequences for the study: 1)
Fluid-Attenuated Inversion Recovery (FLAIR) for segmentation
of the edema and 2) post-contrast T1 weighted imaging (T1WI)
for segmentation of enhancement (defined as tumor) and
necrosis (Figure 1a, b, and c). Peritumoral FLAIR and T2
weighted image (T2WI) hyperintensity in GBM patients reflects
a mixture of edema and tumor infiltration and is routinely used
to evaluate its extent [19,27,28,29]. Thus, these sequences were
selected to compute quantitative edema/invasion volumetry.
We refer to the area of peritumoral FLAIR/T2WI
hyperintensity as the area of edema/invasion. In cases where
FLAIR was not available for segmentation, T2WI or proton
density (PD) sequences were used. In cases where post-contrast
T1WI was not available, the post-contrast Spoiled Gradient
Echo Recalled (SPGR) sequence was used. Standard imaging
parameters were used for each of the sequences as noted in the
TCGA database.
Figure 3. High FLAIR patient. A 59 year old female patient with a left frontal GBM. The segmented edema/tumor infiltration (blue), enhancement
(yellow) and necrosis (orange) are seen overlaid on a base post- contrast T1WI. The images demonstrate a patient with a medium to large GBM with a
relatively small amount of peritumoral FLAIR hyperintensity reflecting edema and tumor infiltration.
doi:10.1371/journal.pone.0025451.g003
Figure 4. Correlation scatter plots. (a) FLAIR vs. Contrast Enhancement and (b) FLAIR vs. Necrosis volumes.
doi:10.1371/journal.pone.0025451.g004
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(http://www.slicer.org) was used for all purposes of image analysis,
manipulation and segmentation. 3D Slicer is an open-source
software platform developed at our institution (BWH/Harvard
Medical School) for medical image processing and 3D
visualization of image data [30,31,32]. The platform provides
functionality for segmentation, registration and 3D visualization of
imaging data and advanced MRI analysis algorithms. Two
neuroradiologists (RRC, FAJ), with more than six (RRC) and 20
(FAJ) years of experience in image segmentation, reviewed the
segmented images in consensus.
Image Registration, Segmentation and Model
Making. To account for FLAIR and post-contrast T1WI
obtained with different slice parameters, angles or voxel thickness,
we rigidly aligned and registered the scans to each other. In some
cases wherethe voxel size ofthe FLAIR and T1W1 series varied, we
resampled the FLAIR volume to the matrix of T1W1 series. In most
scans, registration was 100%. In those scans in which complex
rotation modifications and registrations were required, registration
was deemed adequate when error was 2 mm or less.
Segmentation was carried out in a simple hierarchical model of
anatomy, proceeding from peripheral to central. Three distinct
structures were segmented (edema/invasion, enhancing tumor,
and necrosis). Subsequently, the models of edema, tumor and
necrosis were generated from the previously performed segmen-
tations, and the volumes of the same were automatically
calculated.
Biostatistical Image-Genomic Analysis
Affymetrix level 1 mRNA and Agilent level 2 microRNA data
were downloaded from the public TCGA dataportal (April 2011)
(http://cancergenome.nih.gov/). The raw data files for discovery
and validation sets were separately downloaded and analyzed.
Affymetrix CEL file analysis was performed in R project, a free
statistical computing platform (http://www.r-project.org/) using
the Bioconductor suite (http://www.bioconductor.org/). The
Figure 5. Ingenuity Pathway Analysis top network for mRNA.
doi:10.1371/journal.pone.0025451.g005
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[33].
In each patient, a total of 13,628 genes (22,267 hybridization
probes) and 555 microRNAs (1,510 hybridization probes) were
analyzed for significance and differential fold regulation in high
versus low FLAIR groups by Comparative Marker Selection
(CMS) (Broad Institute, MIT, Cambridge, MA, http://www.
broadinstitute.org/cancer/software/genepattern/). CMS is a sta-
tistical method that uses permutation testing to identify differen-
tially regulated genomic events in one versus another predefined
patient group [34].
The top greater than 1.5 fold differentially expressed and
concordant mRNAs and microRNAs in both the discovery and
validation sets (Table S1 and S2) were then analyzed with Ingenuity
Pathway Analysis (IPA) (http://www.ingenuity.com). IPA provides
insight into the molecular and chemical interactions, cellular
phenotypes, and disease processes of a predefined set of genes and
microRNAs. By means of IPA, our top molecular targets for the
high FLAIR group were analyzed in a comprehensive way and,
thus, pertinent canonical pathways and functional networks
accounting for edema and invasion were uncovered. Using the
total amount of available TCGA patients (April 2011), the Kaplan
Meier method was used to calculate overall- (N=442) and
progression-free (N=303) survival. Mean gene expression across
GBM subgroups was calculated using ANOVA and Tukey-Kramer
tests. For gene and microRNA correlations we used R square
statistics. All calculations were performed in Microsoft Excel 2010
and JMP 9.01 (SAS Institute, CA).
microRNA Target Prediction
Gene target search was performed using miRWalk [35], a
database providing a search function for predicted and validated
microRNA targets. Both predicted and validated gene targets for
the concordant microRNAs in the high FLAIR group (Table S2)
were downloaded and matched with the mRNA hits from the
discovery and validation sets (Table S1).
Results
Patient population
A total of 52 patients were included for analysis (discovery set:
N=26, 8 female, 18 male; validation set: N=26, 9 female, 17
male) (Table 1).
Imaging Analysis
The average FLAIR volumes in the discovery and validation
sets were 82,646 mm
3 and 68,209 mm
3 and did not significantly
differ from each other (P=0.85). The mean FLAIR volume of the
discovery set’s low and high FLAIR group was 33,271 mm
3 and
132,021.5 mm
3, respectively. The mean FLAIR volumes in the
validation set’s low and high groups were 20,705.5 mm
3 and
118,651.6 mm
3 (Figure 2 and 3, Table 1). There was an overall
weak positive correlation between FLAIR and contrast enhance-
ment volumes (R
2=0.13, Figure 4a). There was no correlation
between the FLAIR and necrosis volumes (R
2=0.004, Figure 4b).
Imaging-Genomic Correlation
Gene-expression analysis in high versus low FLAIR groups
revealed top genes and microRNAs greater than 1.5 fold
differentially and concordantly regulated in the discovery and
validation sets. A total of 53 mRNAs (32 high expression; 21 low
expression) and 5 microRNAs (3 high expression; 2 low
expression) were identified (Table S1 and S2).
The discovered mRNA and microRNAs were separately
analyzed in Ingenuity Pathway Analysis (IPA). The top mRNA
disease ontology was Cancer and the top cellular functions were:
Cellular Movement, Cell Morphology, and Cellular Development
(Figure 5; Table 2). The top microRNA disease ontology was
Cancer and the top cellular functions were: Cell Cycle, Cellular
Movement, and Cell Death (Figure 6; Table 3).The top concordant
mRNAsinboththe discoveryandvalidationsetsinvolvedincellular
movement and invasion (N=20) are shown in Figure 7.
The top upregulated gene in both the discovery (4 fold) and
validation (11 fold) sets was PERIOSTIN (POSTN). The top
downregulated microRNA in both sets was miR-219, a microRNA
predicted to bind to POSTN [35] (Figure 8a, b, and c; Table 4, S1,
S2). We then examined POSTN expression and patient survival in
the entire TCGA GBM patient cohort. Kaplan Meier analysis
demonstrated that above median expression of POSTN resulted in
significantly decreased survival (P=0.0008, N=442) and shorter
time to disease progression (P=0.0009, N=303) (Figure 8a and
8b). Furthermore, we analyzed POSTN expression in the two most
extreme GBM molecular subtypes: Mesenchymal and Proneural
[36]. We found that POSTN is significantly upregulated in
Mesenchymal GBM (P,0.0001, Figure 8c). Despite this strong
association with the Mesenchymal subtype, POSTN expression was
a stronger prognostic variable than either molecular subtype in the
Table 2. Top ‘‘Diseases and Cellular functions’’ for mRNA.
Diseases and Disorders P-Value # Molecules
Cancer 2.15E-08 - 1.09E-02 29
Skeletal and Muscular Disorders 6.22E-06 - 8.22E-03 24
Genetic Disorders 7.39E-06 - 8.22E-03 38
Neurological Disease 2.57E-05 - 9.79E-03 27
Reproductive System Disease 3.36E-05 - 8.22E-03 23
Molecular and Cellular Functions P-Value # Molecules
Cellular Movement 1.54E-07 - 1.09E-02 20
Cell Morphology 4.41E-06 - 1.09E-02 16
Cellular Development 7.52E-06 - 1.09E-02 20
Cell-To-Cell Signaling and Interaction 2.15E-05 - 1.09E-02 13
Small Molecule Biochemistry 2.21E-05 - 1.09E-02 12
doi:10.1371/journal.pone.0025451.t002
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P=0.1; data not shown).
Among the five concordant microRNA hits across the discovery
and validation sets (Table S2), a gene target search demonstrated
multiple bioinformatically predicted and inversely expressed genes
in the high FLAIR patient group. There were two top
downregulated microRNAs (Table S2). Interestingly, miR-219
was significantly downregulated in the Mesenchymal GBM
subtype (P,0.0001, Figure 8d) and showed an inverse correlation
with POSTN (Rsq=0.205, Figure 8d) suggesting a potential miR-
219-POSTN regulatory mechanism in GBM cellular invasion.
Interestingly, the other top downregulated microRNAs in the high
FLAIR group, miR-127, was experimentally shown to target
CXCL12 mRNA [37], a major factor for GBM invasion
[25,38,39,40] and also one of our top genes accounting for high
FLAIR volumes (Table 4 and S1).
Discussion
In this study, we present the first comprehensive radiogenomic
analysis using quantitative MRI volumetrics and large-scale gene-
and microRNA expression profiling in GBM. We identified MRI-
FLAIR as an imaging surrogate for GBMs highly enriched in
genes and microRNAs involved in cellular migration/invasion and
specifically identified miR-219 as a potential regulator of cellular
invasion by binding to the 39UTR of the POSTN gene, thus
diminishing POSTN protein levels.
There was a slight positive correlation (Rsq=0.13) (Figure 4a)
between the volumes of contrast enhancement (active tumor) and
peritumoral FLAIR signal abnormality (peritumoral edema and
tumor infiltration). There was no correlation seen between the
FLAIR and necrosis volumes (Figure 4b). These findings suggest
that FLAIR, as an imaging surrogate for edema/invasion,
Figure 6. Ingenuity Pathway Analysis top network for microRNA.
doi:10.1371/journal.pone.0025451.g006
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tumor size and volumes of necrosis. Since areas of peritumoral
FLAIR hyperintensity contain a mixture of both edema and cell
invasion in GBM [19,27,38,41,42,43], we can further hypothesize
that high FLAIR radiophenotypes likely reflect a unique
molecular tumor composition driving cellular migration and
invasion.
Strengthening our above findings and hypothesis, we found in
the high FLAIR patients that the top concordant genes and
microRNAs across both the discovery and validation sets were
highly associated with cancer, cellular movement, cell morphol-
ogy, and cell signaling. A total of 29 of our top 53 genes were
reported to play a role in cancer by IPA, while 20 were reported to
play a role in cellular migration and invasion and 16 were reported
Figure 7. Top functional mRNA network for Cellular Movement/Invasion.
doi:10.1371/journal.pone.0025451.g007
Table 3. Top ‘‘Diseases and Cellular functions’’ for microRNA.
Diseases and Disorders P-Value # Molecules
Cancer 3.31E-06 - 2.00E-02 3
Gastrointestinal Disease 3.31E-06 - 3.31E-06 3
Hepatic System Disease 3.31E-06 - 3.31E-06 3
Inflammatory Disease 1.15E-05 - 6.88E-03 2
Skeletal and Muscular Disorders 1.15E-05 - 1.13E-02 2
Molecular and Cellular Functions P-Value # Molecules
Cell Cycle 1.30E-03 - 1.30E-03 1
Cellular Movement 4.84E-03 - 4.84E-03 1
Cell Death 1.80E-02 - 1.80E-02 1
doi:10.1371/journal.pone.0025451.t003
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means of patient substratification into high and low FLAIR
radiophenotypes, we are able to identify GBM subtypes with genes
and microRNAs accounting for and possibly promoting migration
and invasion. This was true for both mRNA and microRNA
(Figure 5, 6, and 7; Table S1 and S2); across the discovery and
validation sets, there were 5 concordant microRNAs. Despite this
relatively low number, ‘‘cancer’’ and ‘‘cellular movement’’ were
represented among the top diseases and cellular functions in IPA.
Interestingly, the top upregulated gene in both the discovery and
validation sets was POSTN (Table S1), a gene previously implicated
downstream of TWIST1 as being involved in invasion and
mesenchymal transition in vitro [44]. Another report showed POSTN
to be ranked among the top upregulated genes in ovarian cancer and
GBM in both Agilent and Affymetrix microarray platforms [45].
In our study, POSTN expression was significantly associated
with survival and time to disease progression in the TCGA
database (P,0.0009; Figure 8a and 8b). When examining POSTN
in the previously described GBM molecular subtypes [36], we
found significant POSTN upregulation in the Mesenchymal
compared to Proneural GBM subtype (P,0.0001; Figure 8c),
confirming POSTN’s possible role in mesenchymal transition.
POSTN inducing cellular invasion through epithelial-mesenchy-
mal transformation has been described in 293T kidney cell lines
[46,47]. Despite Mesenchymal and Proneural being some
indicator for survival in GBM (P=0.202; data not shown), POSTN
was a stronger predictor and prognostic marker in the Cox
proportional hazards model (POSTN: P=0.03, GBM Subtype:
P=0.1; data not shown). This demonstrates that POSTN also
Table 4. Bioinformatically predicted gene-microRNA
regulatory networks in high FLAIR signal GBMs.
microRNAs genes fold change regulation
miR-219 POSTN 7.45787885 up
miR-127* CXCL12* 1.95140035 up
miR-127 COL1A1 1.69140875 up
miR-127 COL6A3 2.1281926 up
miR-127 GRB10 1.63224725 up
miR-127 SRPX2 1.78434725 up
miR-224 AQP4 21.841773 down
miR-199b KIF1A 21.8371131 down
miR-223 MPPED2 22.12913255 down
miR-223 CTNNA2 21.64381515 down
miR-223 PKP4 21.59000765 down
miR-223 KIF5C 21.54863265 down
*validated binding; bold text=upregulated.
doi:10.1371/journal.pone.0025451.t004
Figure 8. Kaplan Meier curves for Periostin. (a) days to death and (b) progression free survival. (c) Periostin expression levels across the two
main GBM subtypes, Mesenchymal and Proneural. And (d) shows expression levels of miR-219 across the Mesenchymal and Proneural subtypes and
in addition the inverse correlation (Rsq=0.204) with Periostin.
doi:10.1371/journal.pone.0025451.g008
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Therefore, POSTN inhibition can be proposed to target
mesenchymal transition and cancer cell invasion, two major
causes of GBM aggressiveness and failure of current therapy.
The top downregulated microRNA across the discovery and
validation sets was miR-219 (Table S2). Our data show that
POSTN and miR-219 are inversely correlated (Rsq=0.204) and
that this is also true across the Mesenchymal and Proneural
subtypes (P,0.0001; Figure 8d). Interestingly, miR-219 is known
to have a potential binding site in the 39UTR of the POSTN gene
[35]. This suggests a potential role of miR-219 in downregulating
POSTN in GBM mesenchymal transition and cellular invasion.
Most importantly, this signature can be noninvasively detected by
MRI upon initial patient consultation.
CXCL12 and CXCL14 were other top genes associated with the
invasive radiophenotype in the high FLAIR volume group.
CXCL12 is a known chemokine described in invasion and cell
migration and is a ligand of CXCR4, a chemokine receptor that
promotes tumor migration and invasion [25,38,39,40]. McMillan et
al. [25,38] demonstrated an increased T2-signal intensity in GBM
patients with high CXCR4 expression, further corroborating the
validityofinvasionassociated genesinourstudy.Interestingly,miR-
127, the second top downregulated microRNA in the high FLAIR
group, was experimentally shown to target CXCL12 [35,37]. This
and the fact that other inversely correlated mRNAs and
microRNAs with predicted binding sites (Table 4) were uncovered
in our radiogenomics screen, further suggests a role of MRI as an
early screening method for GBM specific molecular compositions
and regulatory microRNA-mRNA mechanisms.
A limitation of the radiological data present in the TCGA is the
lack of image-sample registration; thus, gene expression profiles
cannot be matched to a specific location on MRI. Despite TCGA
samples originating from the contrast enhancing core parts of the
tumor, we showed a strong overrepresentation of migratory and
invasive cell functions with higher peritumoral FLAIR volumes.
Despite previous studies showing a different gene expression
profile of core versus rim tumor parts [48,49,50], our analysis
suggests that the potential of cellular migration and invasion may
already be inherent in the GBM core and can be linked to the
extent of peritumoral FLAIR signal abnormality. These findings
are currently undergoing molecular mechanistic and imaging
validation studies at our institutions. Certain limitations also exist
with the use of microarray technology and analysis, e.g. due to the
large number of probes, false positive gene hits may occur.
However, using stringent false discovery rate correction, both
validation and discovery sets, as well as careful literature cross-
referencing, and microRNA target exploration increases robust-
ness of findings. Finally, prospective validation is needed to fully
establish MRI as a clinically applicable radiogenomics biomarker.
Conclusion
MRI-FLAIR readily and noninvasively detected key cancer
genomic components responsible for cellular migration and
invasion in GBM. It further detected genes and microRNAs
highly associated with mesenchymal transformation and invasion.
As a discovery tool, MRI specifically identified POSTN and miR-
219, suggesting a regulatory network promoting mesenchymal
transition and invasion in GBM.
Since cellular invasion is a major cause of current treatment
failure, surgical extent of resection and adjuvant treatment
planning are of utmost importance. Here, we propose a novel
diagnostic method to screen for cancer subtypes and molecular
correlates of cellular invasion. Our findings also have potential
therapeutic significance since successful molecular inhibition of
invasion will improve therapy and patient survival in GBM.
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